CHINESE JOURNAL OF DRUG EVALUATION >

2025 , Vol. 42 >Issue 5: 373 - 373-377

DOI: https://doi.org/magtech-2025-08-07-00001

Impact of the Timing of Methylprednisolone Administration on Clinical Efficacy in Children with Refractory Mycoplasma Pneumoniae Pneumonia

Expand
  • Pediatrics Department， of the 989th Hospital of the Joint Logistics Support ForceLuoyang， Henan Luoyang 471000， China

Received date: 2025-08-07

  Revised date: 2025-09-12

  Accepted date: 2025-11-27

  Online published: 2025-12-15

Fold

Abstract

Objective： To investigate the impact of the timing of methylprednisolone administration on clinical efficacy in children with refractory Mycoplasma pneumoniae pneumonia (RMPP). Methods： A total of 82 children with RMPP admitted to the Department of Pediatrics， 989 Hospital of the Chinese PLA Joint Logistics Support Force from January 2023 to January 2025 were enrolled in this study. According to the timing of treatment， they were divided into the early group and the late group. The early group was treated with methylprednisolone when the disease course was less than 5 d， while the late group was treated with methylprednisolone when the disease course was 5 d or more. Comparisons were made between the two groups on inflammatory factors [C-reactive protein (CRP)， interleukin (IL)-6， interferon (IFN)-γ]， pulmonary function [peak expiratory flow (PEF)， forced expiratory volume in the first second (FEV1)， forced vital capacity (FVC)]， immune function [immunoglobulin (Ig) A， IgM and CD4+/CD8+]， recovery after treatment (improvement time of fever， cough and pulmonary rales， length of hospital stay)， clinical efficacy and adverse reactions. Results： After treatment， the levels of CRP， IL-6 and IFN-γ in the early group were significantly lower than those in the late group. PEF， FEV1 and FVC were significantly higher than those in the late group (P<0.05). There was no statistically significant difference in IgA， IgM， or CD4+/CD8+ between the two groups after treatment (P>0.05). After treatment， inflammatory factors， pulmonary function， and immune function indicators in both groups were significantly improved (P<0.05). Compared with the late group after treatment， the early group showed significant reductions in the improvement time of fever， cough and pulmonary rales， and length of hospital stay (P<0.05). The total clinical effective rates and the incidence of adverse reactions of the two groups were comparable (P>0.05). Conclusion： Although the timing of methylprednisolone administration has no significant influence on immune function， clinical efficacy and risk of adverse reactions in children with RMPP， early use of methylprednisolone is conducive to lowering the levels of inflammatory factors， enhancing pulmonary function， and promoting the improvement of clinical symptoms.

Key words： Methylprednisolone； Timing of administration； Child； Refractory Mycoplasma pneumoniae pneumonia
 ;   

Cite this article

MA Caihong, YANG Keke, YU Zhihui . Impact of the Timing of Methylprednisolone Administration on Clinical Efficacy in Children with Refractory Mycoplasma Pneumoniae Pneumonia[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2025 , 42(5) : 373 -373-377 . DOI: magtech-2025-08-07-00001

References

 [1] 王璐，李丹梅，司利钢. 血清生物标志物在肺炎支原体肺炎患儿病情发展及预后评估中的应用价值[J]. 中国医刊，2025，60(2)：172-176.
     [2] 黎芮彤，岳玉川，谷续洁，等. 儿童难治性肺炎支原体肺炎风险预测模型的系统评价[J]. 中国全科医学，2025，28(9)：1105-1114.
     [3] 周云连，倪晨. 儿童肺炎支原体对大环内酯类抗菌药物的耐药现状及抗菌药物治疗的研究进展[J]. 浙江医学，2024，46(12)：1233-1238.
     [4] 宁成利，朱占魁，侯杏杏. 喘息性支气管炎患儿经甲泼尼龙和孟鲁司特钠治疗的效果及对运动耐力的影响[J]. 临床和实验医学杂志，2025，24(1)：58-62.
     [5] 国家卫生计生委合理用药专家委员会儿童用药专业组. 中国儿童肺炎支原体感染实验室诊断规范和临床实践专家共识(2019年)[J]. 中华儿科杂志，2020，58(5)：366-373.
     [6] Zhao X， Lv J， Wu M， et al. Clinical characteristics and risk factors for Mycoplasma pneumoniae pneumonia in children[J]. Front Pediatr， 2024， 12：1438631.
     [7] 张睿，刘峰. 炎症指数在儿童肺炎支原体肺炎中的应用进展[J]. 传染病信息，2025，38(1)：89-92，102.
     [8] 韩茜，蒋凯旋，王燕侠，等. 儿童难治性支原体肺炎危险因素的系统评价[J]. 中国循证医学杂志，2021，21(10)：1168-1173.
     [9] 王翠华，杨建功，李敏艳，等. 难治性肺炎支原体肺炎患儿泛免疫炎症值与病情、预后的关系[J]. 国际检验医学杂志，2025，46(8)：1006-1010.
     [10] Li M， Wei X， Zhang SS， et al. Recognition of refractory mycoplasma pneumoniae pneumonia among myocoplasma pneumoniae pneumonia in hospitalized children： development and validation of a predictive nomogram model[J]. BMC Pulm Med， 2023， 23(1)：383.
     [11] 董玲俊，宋宏正. 甲泼尼龙联合丙种球蛋白对肺炎患儿炎症指标的影响[J]. 中国药物与临床，2021， 21(7)：1169-1171.
     [12] Phan PH， Hoang CN， Nguyen HTT， et al. Comparison of methylprednisolone alone versus intravenous immunoglobulin plus methylprednisolone for multisystem inflammatory syndrome in children (MIS-C)[J]. BMJ Paediatr Open， 2025， 9(1)：e003148.
     [13] Liu J， He R， Zhang X， et al. Clinical features and “early” corticosteroid treatment outcome of pediatric mycoplasma pneumoniae pneumonia[J]. Front Cell Infect Microbiol， 2023， 13：1135228.
     [14] 郝红菲，陶沛佩. 甲泼尼龙联合阿奇霉素治疗重症支原体肺炎患儿的疗效及其对肺功能的影响[J]. 河北医药，2024，46(22)：3440-3443.
     [15] 何宜，许丽琴，齐旭升. 甲泼尼龙辅助治疗对支原体肺炎患儿疗效及肺功能的影响[J]. 川北医学院学报，2021，36(12)：1581-1583.
     [16] 梁壮，邸兴伟，李晓东，等. 小剂量甲泼尼龙对中重度急性呼吸窘迫综合征患者肺容积及氧合影响的临床分析[J]. 中国呼吸与危重监护杂志，2021，20(6)：427-431.
     [17] 阮洪云，李琦，陈效友，等. 结核性胸膜炎患者化疗时是否加用糖皮质激素对肺功能动态变化的对比研究[J]. 中国防痨杂志，2021，43(1)：58-65.
     [18] Yang M， Chen Y， Feng C， et al. Single-cell RNA sequencing uncovers molecular mechanisms of intravenous immunoglobulin plus methylprednisolone in Kawasaki disease： attenuated monocyte-driven inflammation and improved NK cell cytotoxicity[J]. Front Immunol， 2024， 15：1455925.
     [19] 陈海丹，张华. 丙种球蛋白联合甲泼尼龙治疗小儿重症支原体肺炎的疗效及对免疫功能、肺功能的影响[J]. 医学综述，2021，27(17)：3525-3530.
     [20] 宋铁军，杨会君，王亚斐，等. 早期应用糖皮质激素治疗带状疱疹临床观察及对淋巴细胞亚群的影响[J]. 中华保健医学杂志，2021，23(2)：179-180.
     [21] Boglione L， Olivieri C， Rostagno R， et al. Role of the early short-course corticosteroids treatment in ARDS caused by COVID-19： A single-center， retrospective analysis[J]. Adv Med Sci， 2021， 66(2)：262-268.
     [22] Xia Q， Dai W， Xu K， et al. Clinical efficacy of methylprednisolone and the combined use of lopinavir/ritonavir with arbidol in treatment of coronavirus disease 2019[J]. J Med Virol， 2021， 93(7)：4446-4453.
Options
Outlines

/

〈 〉

[an error occurred while processing this directive]